Search Results - "Berney, D"

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort by Cuzick, J, Berney, D M, Fisher, G, Mesher, D, Møller, H, Reid, J E, Perry, M, Park, J, Younus, A, Gutin, A, Foster, C S, Scardino, P, Lanchbury, J S, Stone, S

“…Background: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP)…”
Get full text

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up by Oldenburg, J., Berney, D.M., Bokemeyer, C., Climent, M.A., Daugaard, G., Gietema, J.A., De Giorgi, U., Haugnes, H.S., Huddart, R.A., Leão, R., Sohaib, A., Gillessen, S., Powles, T.

“…•This ESMO Clinical Practice Guideline provides key recommendations on the management of testicular seminoma and non-seminoma.•Authorship includes a…”
Get full text

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort by Fisher, G, Yang, Z H, Kudahetti, S, Møller, H, Scardino, P, Cuzick, J, Berney, D M

“…Background: Standard clinical parameters cannot accurately differentiate indolent from aggressive prostate cancer. Our previous work showed that…”
Get full text

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice by Newton, C., Murali, K., Ahmad, A., Hockings, H., Graham, R., Liberale, V., Sarker, S.-J., Ledermann, J., Berney, D.M., Shamash, J., Banerjee, S., Stoneham, S., Lockley, M.

“…Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will…”
Get full text

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up by Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., Fizazi, K., Fosså, S., Germa-Lluch, J.R., Giannatempo, P., Gietema, J.A., Gillessen, S., Haugnes, H.S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M.A.S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondruš, D., Papachristofilou, A., Powles, T., Sohaib, A., Ståhl, O., Tandstad, T., Toner, G., Horwich, A.

“…The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3–5 November 2016 in Paris, France. The conference…”
Get full text

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib by Welti, J C, Gourlaouen, M, Powles, T, Kudahetti, S C, Wilson, P, Berney, D M, Reynolds, A R

“…The vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor sunitinib has been approved for first-line treatment of patients with…”
Get full text

Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort by Cuzick, J, Stone, S, Fisher, G, Yang, Z H, North, B V, Berney, D M, Beltran, L, Greenberg, D, Møller, H, Reid, J E, Gutin, A, Lanchbury, J S, Brawer, M, Scardino, P

“…Background: The natural history of prostate cancer is highly variable and difficult to predict accurately. Better markers are needed to guide management and…”
Get full text

WHO 2022 classification of penile and scrotal cancers: updates and evolution by Menon, S, Moch, H, Berney, DM, Cree, IA, Srigley, JR, Tsuzuki, T, Compérat, E, Hartmann, A, Netto, G, Rubin, MA, Gill, AJ, Turajlic, S, Tan, PH, Raspollini, MR, Tickoo, SK, Amin, M B

“…Squamous cell carcinoma (SCC) is the most common malignant tumour of the penis. The 2022 WHO classification reinforces the 2016 classification and…”
Get full text

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer by Attard, G, Clark, J, Ambroisine, L, Fisher, G, Kovacs, G, Flohr, P, Berney, D, Foster, C S, Fletcher, A, Gerald, W L, Moller, H, Reuter, V, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S

“…New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of…”
Get full text

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer by Cuzick, J, Yang, Z H, Fisher, G, Tikishvili, E, Stone, S, Lanchbury, J S, Camacho, N, Merson, S, Brewer, D, Cooper, C S, Clark, J, Berney, D M, Møller, H, Scardino, P, Sangale, Z

“…Background: The natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of phosphatase and tensin…”
Get full text

The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas by Tufton, N, Hearnden, R J, Berney, D M, Drake, W M, Parvanta, L, Chapple, J P, Akker, S A

“…Emerging evidence suggests the composition of the tumour microenvironment (TME) correlates with clinical outcome and that each tumour type has a unique TME…”
Get full text

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer by Reid, A H M, Attard, G, Ambroisine, L, Fisher, G, Kovacs, G, Brewer, D, Clark, J, Flohr, P, Edwards, S, Berney, D M, Foster, C S, Fletcher, A, Gerald, W L, Møller, H, Reuter, V E, Scardino, P T, Cuzick, J, de Bono, J S, Cooper, C S

“…Background: The discovery of ERG/ETV 1 gene rearrangements and PTEN gene loss warrants investigation in a mechanism-based prognostic classification of prostate…”
Get full text

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer by Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.

“…The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated. Two…”
Get full text

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study by Berney, D M, Gopalan, A, Kudahetti, S, Fisher, G, Ambroisine, L, Foster, C S, Reuter, V, Eastham, J, Moller, H, Kattan, M W, Gerald, W, Cooper, C, Scardino, P, Cuzick, J

“…Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of…”
Get full text

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma by Bharwani, N, Miquel, M E, Powles, T, Dilks, P, Shawyer, A, Sahdev, A, Wilson, P D, Chowdhury, S, Berney, D M, Rockall, A G

“…Background: Current imaging criteria for categorising disease response in metastatic renal cell carcinoma (mRCC) correlate poorly with overall survival (OS) in…”
Get full text

Complex patterns of ETS gene alteration arise during cancer development in the human prostate by Clark, J, Attard, G, Jhavar, S, Flohr, P, Reid, A, De-Bono, J, Eeles, R, Scardino, P, Cuzick, J, Fisher, G, Parker, M D, Foster, C S, Berney, D, Kovacs, G, Cooper, C S

“…An ERG gene ‘break-apart’ fluorescence in situ hybridization (FISH) assay has been used to screen whole-mount prostatectomy specimens for rearrangements at the…”
Get full text

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement by Foster, C S, Dodson, A R, Ambroisine, L, Fisher, G, Møller, H, Clark, J, Attard, G, De-Bono, J, Scardino, P, Reuter, V E, Cooper, C S, Berney, D M, Cuzick, J

“…Background: This study was performed to test the hypothesis that expression of small heat shock protein Hsp-27 is, at diagnosis, a reliable predictive…”
Get full text

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer by Powles, T., Kayani, I., Sharpe, K., Lim, L., Peters, J., Stewart, G.D., Berney, D., Sahdev, A., Chowdhury, S., Boleti, E., Shamash, J., Reynolds, A.R., Jones, R., Blank, C., Haanen, J., Bex, A.

“…Vascular endothelial growth factor (VEGF)-targeted therapy is administered continuously until progression in metastatic clear cell renal cancer (mRCC). The…”
Get full text

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer by Ahmad, I, Singh, L B, Yang, Z H, Kalna, G, Fleming, J, Fisher, G, Cooper, C, Cuzick, J, Berney, D M, Møller, H, Scardino, P, Leung, H Y

“…Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)–extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been…”
Get full text

Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer by Merson, S, Yang, Z H, Brewer, D, Olmos, D, Eichholz, A, McCarthy, F, Fisher, G, Kovacs, G, Berney, D M, Foster, C S, Møller, H, Scardino, P, Cuzick, J, Cooper, C S, Clark, J P

“…Background: Androgen receptor ( AR )-gene amplification, found in 20–30% of castration-resistant prostate cancer (CRPCa) is proposed to develop as a…”
Get full text